Status:
ENROLLING_BY_INVITATION
A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
Lead Sponsor:
Xi Tan
Conditions:
Psoriasis
Eczema
Eligibility:
All Genders
18-65 years
Brief Summary
Emerging evidence indicates that psoriasis and eczema can coexist in the same patient, with reported co-prevalence rates ranging from 0.17% to 20%, suggesting that these conditions may represent a dis...
Detailed Description
Eczema-like psoriasis, also referred to as psoriasis-eczema overlap, is a distinct clinical and immunopathological entity that presents with features of both chronic plaque psoriasis and atopic dermat...
Eligibility Criteria
Inclusion
- patients who present typical psoriasis and typical eczema; 2.patients present untypical psoriasis lesions, biopsy result reveals both psoriasis and eczema features; 3.BSA≥3 and IGA≥3.
Exclusion
- ① Local use of therapeutic drugs (such as glucocorticoids, calcineurin inhibitors, etc.) within 2 weeks Vitamin D derivatives, retinoid drugs); Received biological treatment within 4 weeks or 4 half lives Agents or their immunosuppressive/immunomodulatory agents (such as cyclosporine, methotrexate, JAK inhibitors);
- Suffering from active autoimmune diseases; Active tuberculosis infection; Hepatitis B surface antigen positive; Uncontrolled systemic diseases such as heart failure, cerebrovascular disease, and liver and kidney dysfunction;
- Known or suspected history of immunosuppression, or although the infection has disappeared, it has been assessed by the researcher as possible Frequent publication of authors;
- History of malignant tumors in the past, or current occurrence of any malignant tumors (excluding basal tumors cured for ≥ 1 year) Cell carcinoma, local squamous cell carcinoma of the skin, or cervical cancer in situ;
- Pregnant or lactating women, or those with pregnancy plans during the trial period.
Key Trial Info
Start Date :
April 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06999941
Start Date
April 24 2025
End Date
August 30 2026
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai general hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200080